InterVenn: Peninsula biotech InterVenn terminates South San Francisco lease amid flooded life sciences market
The company, which has raised close to $300 million, counts among its founders Carolyn Bertozzi, a Stanford University chemistry professor and 2022 winner of the Nobel Prize.
Read full article »
InterVenn is a California-based AI glycoproteomics platform that offers solutions such as biomarker research and liquid biopsy assay development for the healthcare industry.
Read more